BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX

Zacks11-19

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484923319?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","is_english":true,"pubTime":"2024-11-19 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484923319","market":"us","top_or_hot":-1,"title":"BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX","media":"Zacks","content":"<div>\n<p>Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device...</p>\n\n<a href=\"https://finance.yahoo.com/news/bsx-stock-gains-positive-option-132200283.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bsx-stock-gains-positive-option-132200283.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device...</p>\n\n<a href=\"https://finance.yahoo.com/news/bsx-stock-gains-positive-option-132200283.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0187121727.USD","symbol_name":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/bsx-stock-gains-positive-option-132200283.html","article_id":"2484923319","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484923319","pubTimestamp":1732022520,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure  device. The trial data provided clinical evidence indicating that LAAC with the WATCHMAN FLX device is safe and superior to oral anticoagulation  therapy for reducing the risk of long-term bleeding events in patients who have undergone an ablation.The OPTION trial data were presented at the American Heart Association's Scientific Sessions 2024 and published in the New England Journal of Medicine.In addition to the OPTION trial, the WATCHMAN technology is being evaluated against DOAC therapy in lower-risk patients within the CHAMPION-AF randomized trial. The latest-generation WATCHMAN FLX Pro LAAC device is similarly being studied in several clinical trials, including the SIMPLAAFY randomized controlled t","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","RMD.AU":"Resmed DRC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BSX.AU":"BLACKSTONE MINERALS LTD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","GMED":"Globus Medical Inc","HAE":"美国血液技术","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4082":"医疗保健设备","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","RMD":"瑞思迈","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4131":"航空货运与物流","FLX":"闪送","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","BK7501":"新冠治疗股","BK7095":"多种金属与采矿","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BSX":"波士顿科学","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4581":"高盛持仓"},"translate_title":"WATCHMAN FLX的积极期权试验数据使BSX股票上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1,"RMD":1,"GMED":1,"FLX":1,"BSX":1,"BSX.AU":1,"RMD.AU":0.9},"content_text":"Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device. The trial data provided clinical evidence indicating that LAAC with the WATCHMAN FLX device is safe and superior to oral anticoagulation (OAC) therapy for reducing the risk of long-term bleeding events in patients who have undergone an ablation. \nThe OPTION trial data were presented at the American Heart Association's Scientific Sessions 2024 and published in the New England Journal of Medicine.\nBSX’s Likely Stock Trend Following the News\nFollowing the announcement, shares of BSX moved north 4% to $90.45 yesterday. The company’s structural heart programs are building momentum, banking on the strong performance of the WATCHMAN LAAC device. The next-generation WATCHMAN FLX and FLX Pro are strongly capturing the global market. In the third quarter of 2024, WATCHMAN’s organic sales grew 18% year over year. Accordingly, we expect market sentiment to remain positive surrounding the announcement. \nBSX currently has a market capitalization of $128.1 billion. It has an earnings yield of 17.1%, much higher than the industry’s 12.6%.\nMore on WATCHMAN FLX’s Favorable Trial Data\nThe trial met the primary safety endpoint of non-procedural major bleeding or clinically relevant non-major bleeding at 36 months. In line with this, the WATCHMAN FLX device was found to be superior to OAC. Notably, trial data showed high rates of procedural success in patients who had a WATCHMAN FLX implant after an ablation, which reinforced positive outcomes such as low rates of ischemic and hemorrhagic stroke within the trial population. These positive primary outcomes indicate that patients receiving the WATCHMAN FLX device can eliminate long-term medication use while maintaining stroke protection.\nWith this positive data, the company aims to expand the indication for the WATCHMAN FLX platform. \nAbout OPTION Trial\nThe randomized, controlled OPTION trial included 1,600 patients enrolled across 114 sites in the United States, Europe and Australia. In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. Nearly 40% of the other device patients had the two procedures performed concomitantly, with the WATCHMAN FLX implant taking place after the ablation.\nThe study compared the device with first-line OAC therapy, which included direct oral anticoagulants (DOAC) (95%) and warfarin (5%) for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation. \nMore on the News \nIn addition to the OPTION trial, the WATCHMAN technology is being evaluated against DOAC therapy in lower-risk patients within the CHAMPION-AF randomized trial. The latest-generation WATCHMAN FLX Pro LAAC device is similarly being studied in several clinical trials, including the SIMPLAAFY randomized controlled trial, which is evaluating a single-drug alternative to dual antiplatelet therapy as a post-procedural regimen.\nImage Source: Zacks Investment Research\nIndustry Prospects Favor BSX\nAccording to a Precedence Research report, the global left atrial appendage closure devices market is projected to grow around $7.01 billion by 2034, at a compound annual growth rate of 14.1% from 2024 to 2034. The rising prevalence of atrial fibrillation and rising government initiatives contribute to the market's growth. Technological advancements are also promoting growth. \nBSX’s Recent Development\nThe company recently acquired Axonics, Inc. at an equity value of $3.7 billion.  \nBSX’s Price Performance\nIn the past year, shares of BSX have risen 66.1% compared with the industry’s 21.4% growth. \nBSX’s Zacks Rank and Key Picks\nBSX currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Globus Medical GMED and ResMed RMD. While ResMed carries a Zacks Rank #1 (Strong Buy), Haemonetics and Globus Medical carry a Zacks Rank  #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nHaemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year.\nEstimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.\nEstimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484923319"}